Regenovue Fine Plus with Lidocaine (1 x 1.1ml)

Regenovue

Aesthetic Injectable / Dermal Filler

Cross-linked hyaluronic acid dermal filler for fine lines

CE Marked hyaluronic acid dermal filler (classification subject to regional medical device regulations).
Manufactured under a quality management system consistent with ISO 13485 for medical devices.
Non Animal, highly purified hyaluronic acid with low endotoxin and low residual BDDE levels within accepted international safety limits.

CE Marked hyaluronic acid dermal filler (classification subject to regional medical device regulations).
Manufactured under a quality management system consistent with ISO 13485 for medical devices.
Non Animal, highly purified hyaluronic acid with low endotoxin and low residual BDDE levels within accepted international safety limits.

Cross-linked hyaluronic acid dermal filler for fine lines

Description

Regenovue Fine Plus with Lidocaine (1 x 1.1ml) is a soft, highly cross-linked hyaluronic acid dermal filler specifically designed for the correction of superficial to moderate fine lines and wrinkles. Developed by NeoGenesis using new-generation production technology, it features 24 mg/ml non-animal HA and 0.3% lidocaine in a stable, monophasic, 100% cross-linked gel structure. The filler is ideal for treating delicate areas such as perioral lines around the lips, periorbital lines (crow’s feet) and is widely used for Russian lip techniques. It delivers instant, natural-looking results with effects typically lasting 8–12 months and is completely dissolvable and fully absorbed by the skin over time. The product is intended exclusively for professional use by trained aesthetic practitioners.

Bnefits

Targets fine lines and superficial wrinkles, especially in delicate perioral and periorbital areas.
Contains lidocaine (0.3%) to reduce injection discomfort and improve patient experience.
Longer-lasting results, typically 8–12 months, depending on treatment area, technique and patient factors.
Completely dissolvable and fully absorbed by the skin over time, allowing reversible and adjustable outcomes.
Stable, monophasic, 100% cross-linked HA gel providing consistent, predictable performance and natural integration.
High viscosity yet soft gel texture that allows precise placement and smooth correction without significant lumping when properly injected.
Highly purified, non-animal, biocompatible hyaluronic acid with low endotoxin and low residual BDDE levels.
Easy to inject and handle, supplied in a pre-filled ready-to-use syringe with appropriate needles.

Indications

Correction of fine lines and superficial wrinkles in the upper dermis.
Perioral lines around the lips (smoker’s lines, lipstick lines).
Periorbital wrinkles (crow’s feet) and other fine lines around the eyes.
Glabellar and forehead fine lines (when appropriate product and depth are chosen by the practitioner).
Subtle lip contouring and volume enhancement, including Russian Lips technique, where a softer filler is desired.
Refinement of facial contours and mild improvement of neck folds and fine lines.

Composition

Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
Lidocaine hydrochloride 3 mg/ml (0.3%) as a local anaesthetic.
Physiological phosphate-buffered saline solution at approximately neutral pH.
Very low endotoxin content and low residual BDDE after purification.

Formulation

Monophasic, highly cross-linked hyaluronic acid gel with uniform molecular structure.
Soft, high-viscosity gel formulated for injection into the upper to mid dermis.
1.1 ml pre-filled sterile glass syringe with Luer-lock fitting.
Supplied with 1 x 27G and 1 x 30G sterile needles (varies slightly by distributor), suitable for superficial and delicate areas.
Non-animal stabilised HA, gradually resorbed through natural metabolic processes.

Packaging

Each box contains 1 x 1.1 ml pre-filled syringe of Regenovue Fine Plus with Lidocaine.
Pack usually includes 2 sterile needles (commonly 27G and 30G) and an instruction leaflet.
Syringe is packed in a sterile blister tray with tamper-evident seal inside an outer carton.
Outer packaging displays product name, batch number, expiry date, HA and lidocaine concentrations, manufacturer and regulatory markings.
Labelled for professional use only and distributed through medical/aesthetic channels.

Usage

For intradermal use only by licensed, appropriately trained medical or aesthetic practitioners.
Take a full medical history, evaluate indications and contraindications, and obtain informed consent before treatment.
Clean and disinfect the treatment area thoroughly; topical anaesthetic may be used in addition to the lidocaine in the product, according to clinic protocol.
Allow the pre-filled syringe to reach room temperature before injection. Using aseptic technique, attach a suitable sterile needle (27G or 30G) securely to the Luer-lock syringe.
Inject small amounts of product into the upper to mid dermis using appropriate techniques such as linear threading, serial puncture, micro-droplet or fanning, depending on the area and desired outcome.
Common treatment areas include perioral lines, periorbital lines (crow’s feet), fine glabellar and forehead lines, and lips (Russian Lips and subtle enhancement).
Inject slowly and evenly, avoiding overcorrection; massage lightly if needed to distribute the gel and smooth any irregularities, taking care not to exert excessive pressure.
After the procedure, advise patients to avoid touching or massaging treated areas (unless specifically instructed), intense exercise, alcohol consumption, and exposure to extreme heat (sauna, sunbeds) for 24–48 hours.
Recommend avoiding makeup on the treated area on the day of injection and applying broad-spectrum sunscreen when outdoors.
Schedule follow-up as required to assess results and determine if any touch-up treatment is needed. Dispose of used needles and syringes immediately in approved sharps containers; do not reuse.

Contraindications

Known hypersensitivity or allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics or any other component of the product.
History of severe anaphylactic reactions or multiple serious allergies without appropriate specialist assessment.
Active skin infection, inflammation, herpetic lesions or dermatologic disease at or near the planned injection site.
Pregnancy and breastfeeding, as elective cosmetic filler procedures are generally not recommended.
Autoimmune disorders, uncontrolled systemic diseases or significant immunosuppression, unless treatment is specifically approved by a physician.
Bleeding disorders or concurrent use of anticoagulants/antiplatelets that significantly increase bleeding risk, unless carefully evaluated and managed.
Previous permanent or semi-permanent fillers in the targeted area where interaction may increase risk of complications.
Do not inject into blood vessels or areas with high risk of vascular compromise; intravascular injection is strictly contraindicated.

Adverse Effects

Common, usually transient effects at injection site: redness, swelling, tenderness, bruising, itching, mild pain or firmness.
Temporary small lumps, nodules or unevenness, which often resolve spontaneously or with gentle massage if appropriate.
Occasional prolonged oedema, local inflammatory reaction, or infection requiring medical management.
Rare but serious complications from inadvertent intravascular injection, including vascular occlusion, tissue ischaemia and necrosis, or ocular complications such as visual disturbance or blindness; immediate emergency treatment is required if these occur.
Hypersensitivity or delayed inflammatory reactions, which may manifest as persistent swelling, induration, erythema or discomfort; product use should be stopped and appropriate evaluation undertaken.

Storage Conditions

Store in original packaging at a controlled temperature, typically between 2°C and 25°C (as indicated on the pack).
Protect from freezing and from direct sunlight or heat sources.
Do not use after the expiry date printed on the packaging.
Do not use if the blister pack, syringe or tamper-evident seal is damaged, or if the gel appears cloudy or contains visible particles.
Keep out of reach of children and unauthorised persons.

Duration

Typical duration of effect is approximately 8\u201312 months, varying with treatment area, injection technique, patient metabolism and lifestyle.

Onset

Visible improvement is usually immediate post-injection, with optimal results observed after initial swelling and redness resolve over several days (up to about 2 weeks).